Haleon in the news

Haleon's stock is slipping due to growth worries and a negative catalyst watch from JPMorgan ahead of its upcoming quarterly update.

JPMorgan lowered its price target for Haleon stock due to expected Q3 sales growth at the low end of guidance, despite strong first-half profit conversion.

JPMorgan cut its price target for Haleon stock to 295 GBp and put it on Negative Catalyst Watch due to anticipated lower Q3 growth and reduced future earnings forecasts.

Haleon appointed Vandana Chamaria as the Head of Oral Health for South Asia, leveraging her extensive experience across diverse sectors.

Vandana Chamaria has joined Haleon as the Head of Oral Health for South Asia, bringing over two decades of experience in marketing and business strategy.

Haleon appointed Vandana Chamaria as Head of Oral Health for South Asia, leveraging her 23 years of experience in marketing and business strategy.

Vandana Chamaria is the new Head of Oral Health for South Asia at Haleon, marking her return to consumer health with a wealth of marketing and leadership experience from various sectors.

Haleon PLC's shares declined on Thursday amid a general market downturn, closing significantly below its 52-week high.

Haleon's stock fell 3.0% due to analyst concerns about its growth prospects, as first-half organic revenue growth was below target and future performance depends on improved market conditions.

The document highlights three British AI healthcare stocks (Haleon, IXICO, and AstraZeneca) that are using AI to enhance various aspects of their operations, from product development to clinical trials.

Haleon (HLN) reported 8.81 billion issued ordinary shares, including 11.76 million treasury shares, and 8.80 billion shares with voting rights as of September 30, 2026.

Haleon plc stock is down amid analyst downgrades and concerns about future earnings, despite strong financial fundamentals.

Haleon stock is down 3.17% on October 1, 2026, due to regulatory concerns and litigation, with analysts cutting price targets and placing a "Negative Catalyst Watch" ahead of the October 29 earnings.

Haleon's defensive stock recently saw investors rotate towards cyclical sectors due to lower oil prices and bond yields, despite the consistent demand for consumer health products.

The document lists ETFs that include Haleon PLC Sponsored ADR stocks, sorted by market value, to offer accessible investment opportunities with lower risk.

JPMorgan expressed a cautious outlook on Haleon, citing concerns about its growth, weak volume, cost-cutting-driven margin expansion, and its stock trading near a twelve-month low.

J.P. Morgan has put Haleon on a negative Catalyst Watch due to weak sales momentum and anticipated difficulties in meeting medium-term growth targets.

JPMorgan placed Haleon on a negative catalyst watch and cut its price target, while other analysts adjusted price targets for various London-listed companies.

JPMorgan cut its price target and maintained an Underweight rating on Haleon stock, citing growing risks to its medium-term growth targets due to weak sales and market share loss.

Haleon boosted behavioral science adoption in its teams by embedding it in delivery, focusing on practical outcomes, and leveraging peer influence.